A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers

Journal of Clinical Virology

Volumn 59, Issue 3, 2014, Pages 161-166

  Vasiljević, Nataša ^a   Scibior Bentkowska, Dorota ^a   Brentnall, Adam ^a   Cuzick, Jack ^a   Lorincz, Attila ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

High risk human papillomavirus; L1; L2; Methylation; Pyrosequencing

Indexed keywords

HIGH RISK HUMAN PAPILLOMAVIRUS; L1; L2; METHYLATION; PYROSEQUENCING;

ADULT; ALPHAPAPILLOMAVIRUS; COHORT STUDIES; DNA METHYLATION; DNA, VIRAL; FEMALE; GENOME, VIRAL; HUMANS; PRECANCEROUS CONDITIONS; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC; UTERINE CERVICAL NEOPLASMS;

EID: 84893932827     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.12.014     Document Type: Article

References (24)

1. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
2. Bruni L., Diaz M., Castellsague X., Ferrer E., Bosch F.X., de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2012, 202:1789-1799.
3. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
4. IARC handbooks of cancer prevention 2005, Cervix Cancer Screening, IARC Press, Lyon.
5. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012, 137:516-542.
6. Castle P.E., de Sanjose S., Qiao Y.L., Belinson J.L., Lazcano-Ponce E., Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 2012, 30(Suppl. 5):F117-F122.
7. Cuzick J., Bergeron C., Doeberitz M.K., Gravitt P.E., Jeronimo J., Lorincz A., et al. New technologies and procedures for cervical cancer screening. Vaccine 2012, 30:F107-F116.
8. Lazcano-Ponce E., Lorincz A.T., Cruz-Valdez A., Salmeron J., Uribe P., Velasco-Mondragon E., et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011, 378:1868-1873.
9. Portela A., Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010, 28:1057-1068.
10. Kalantari M., Calleja-Macias I.E., Tewari D., Hagmar B., Lie K., Barrera-Saldana H.A., et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 2004, 78:12762-12772.
11. Sun C., Reimers L.L., Burk R.D. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol 2011, 121:59-63.
12. Mirabello L., Schiffman M., Ghosh A., Rodriguez A.C., Vasiljevic N., Wentzensen N., et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2012, 132:1412-1422.
13. Lorincz A.T., Brentnall A.R., Vasiljevic N., Scibior-Bentkowska D., Castanon A., Fiander A., et al. HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer 2013, 133(3):637-644.
14. Mirabello L., Sun C., Ghosh A., Rodriguez A.C., Schiffman M., Wentzensen N., et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012, 104:1-10.
15. Turan T., Kalantari M., Calleja-Macias I.E., Cubie H.A., Cuschieri K., Villa L.L., et al. Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression. Virology 2006, 349:175-183.
16. Turan T., Kalantari M., Cuschieri K., Cubie H.A., Skomedal H., Bernard H.U. High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology 2007, 361:185-193.
17. Wentzensen N., Sun C., Ghosh A., Kinney W.K., Mirabello L., Wacholder S., et al. Methylation of HPV18, HPV31, and HPV45 genomes is associated with cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012, 104:1738-1749.
18. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
19. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2010, 128:927-935.
20. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006, 100:229-235.
21. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008, 17:3033-3042.
22. Szarewski A., Mesher D., Cadman L., Austin J., Ashdown-Barr L., Ho L., et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the predictors 2 study. J Clin Microbiol 2012, 50:1867-1873.
23. Vasiljevic N., Wu K., Brentnall A.R., Kim D.C., Thorat M., Kudahetti S.C., et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Disease Markers 2011, 30:151-161.
24. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser 1995, 57:289-300.